NDAINHALATIONLIQUID
Approved
Sep 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
12
Data completeness
4/8 — Partial
SUPRANE (desflurane) by Baxter International is 12. First approved in 1992.
Drug data last refreshed 3h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUPRANE (desflurane) is a volatile inhalational general anesthetic used for induction and maintenance of anesthesia in surgical procedures. It works by rapidly modulating neural transmission through potentiation of inhibitory and depression of excitatory neurotransmission. The drug enables quick emergence and recovery, making it particularly suitable for outpatient and ambulatory surgery.
LOE Approaching
Product approaching loss of exclusivity with minimal linked commercial positions (3 jobs), suggesting consolidating team focused on market defense rather than growth.
Mechanism of Action
12.2 Pharmacodynamics Changes in the clinical effects of desflurane rapidly follow changes in the inspired concentration. The duration of anesthesia and selected recovery measures for desflurane are given in the following tables: In 178 female outpatients undergoing laparoscopy, premedicated with…
Worked on SUPRANE at Baxter International? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.